Neuland Laboratories is set to open a new commercial peptide manufacturing facility in the summer of 2026 at its 17-acre Bonthapally campus. The facility represents the first phase of a planned four-module expansion, designed to scale operations in line with growing client demand for complex peptides and GLP-1 programs.
The first module is expected to become operational by this summer, enhancing Neuland’s existing clinical-stage S-Block facilities with commercial-scale capabilities. Module One has already secured firm commitments totaling approximately USD 30 million, highlighting strong market confidence.
Advanced Capacity for SPPS and LPPS Production
Module One will deliver 6,370 liters of reactor capacity for both solid-phase peptide synthesis (SPPS) and liquid-phase peptide synthesis (LPPS). The setup will accommodate LPPS reactors ranging from 250 L to 3,000 L and SPPS reactors up to 500 L, enabling clients to scale seamlessly from small-scale development to multi-ton commercial production. Construction began last year, emphasizing flexibility for long-chain and complex peptide programs while supporting a diverse client portfolio.
Meeting Growing Global Demand for GLP-1 and Novel Peptides
With GLP-1 manufacturing consuming an increasing share of global peptide capacity, Neuland targets both innovator and emerging biotech companies seeking reliable clinical and commercial manufacturing. Saharsh Davuluri, Vice Chairman and MD at Neuland Labs, stated, “The site is designed for ongoing expansion, with space for additional SPPS synthesizers of 2kL and multiple 5kL LPPS reactors as future modules come online. This approach allows us to scale responsibly in line with customer needs.”
Workforce Expansion and Integrated R&D Support
Neuland plans double-digit growth in R&D headcount this year, while its manufacturing team will more than double to support facility ramp-up. These efforts complement 1,174,000 L of existing API manufacturing capacity across three US FDA–approved facilities. An integrated R&D Centre, located near the new plant, ensures rapid technology transfer, efficient scale-up, and streamlined development-to-commercial execution, supporting Neuland’s reputation as a trusted CDMO for complex APIs.
Strategic Entry into Commercial Peptide Manufacturing
The new facility marks Neuland’s strategic entry into commercial-scale peptide production, targeting both novel peptide development and high-demand GLP-1 programs. Davuluri emphasized, “Our goal is to support innovator and emerging biotech companies across all areas of peptide development. Commercial peptide production will be a key growth driver for Neuland over the coming years, and we are scaling rapidly to align rollout of all modules with customer demand.”
Enhanced Digital Systems and Downstream Capabilities
The facility features advanced digital operations, including DCS-based automation with eBMR integration, and scalable peptide technologies across synthesis, purification, and drying.
Expanded downstream infrastructure includes:
*Multi-column prep-HPLC systems
*Lyophilizers and dryers sized for commercial campaigns
*Enhanced solvent-handling and tank-farm infrastructure
*Dedicated warehouses and upgraded waste-management systems
These systems ensure data-rich process development, reduced batch variability, and improved cycle times, while strengthening supply-chain resilience for complex peptides through LPPS capabilities and secure supply of building blocks, fragments, and hybrid constructs.
Strong Regulatory Track Record and Market Momentum
As per the press release, Neuland’s growth comes after several successful NDA filings on behalf of customers, with additional submissions expected over the next two years. The new facility reinforces Neuland’s regulatory compliance, manufacturing excellence, and commercial readiness for peptide clients globally.
